Hemophilia A and hemophilia B: Different types of diseases?

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 7, 2013, Pages 697-701

  Santagostino, Elena ^a   Fasulo, Maria Rosaria ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

bleeding symptoms; factor IX; factor VIII; genotype; hemophilia A; hemophilia B; phenotype

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANAPHYLAXIS; ARTICLE; BLEEDING; BLEEDING TENDENCY; BLOOD SAMPLING; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTRON; MISSENSE MUTATION; MOLECULAR GENETICS; NEPHROTIC SYNDROME; NONSENSE MUTATION; PHENOTYPE; POSTOPERATIVE HEMORRHAGE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCORING SYSTEM; SUBSTITUTION THERAPY; SYMPTOM; TREATMENT OUTCOME;

HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 84885052482     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1353996     Document Type: Article

References (39)

1. Mannucci P. M., Tuddenham E. GD. The hemophilias-from royal genes to gene therapy. N Engl J Med: 2001; 344 23 1773 1779 (Pubitemid 32497033)
2. Berntorp E., Shapiro A. D. Modern haemophilia care. Lancet: 2012; 379 9824 1447 1456
3. Stonebraker J. S., Bolton-Maggs P. H., Soucie J. M., Walker I., Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia: 2010; 16 1 20 32
4. White G. C. II, Rosendaal F., Aledort L. M., Lusher J. M., Rothschild C., Ingerslev J. Factor VIII and Factor IX Subcommittee Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost: 2001; 85 3 560 (Pubitemid 32233035)
5. Aledort L. M., Haschmeyer R. H., Pettersson H. The Orthopaedic Outcome Study Group A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med: 1994; 236 4 391 399 (Pubitemid 24323199)
6. Aznar J. A., Magallón M., Querol F., Gorina E., Tusell J. M. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia: 2000; 6 3 170 176 (Pubitemid 30312470)
7. Solimeno L. P., Mancuso M. E., Pasta G., Santagostino E., Perfetto S., Mannucci P. M. Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution. Br J Haematol: 2009; 145 2 227 234
8. Jayandharan G. R., Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost: 2008; 34 1 128 141 (Pubitemid 351640888)
9. Schulman S., Eelde A., Holmström M., Ståhlberg G., Odeberg J., Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost: 2008; 6 7 1113 1121 (Pubitemid 351859120)
10. Lowe G. D., Ludlam C. A. Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost: 2008; 6 11 1982 1983
11. Tagariello G., Iorio A., Santagostino E., et al. Italian Association Hemophilia Centre (AICE) Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood: 2009; 114 4 779 784
12. Makris M. Is VIII worse than IX? Blood: 2009; 114 4 750 751
13. Haemophilia A-Summary of Unique Mutations reported. Available at: http://hadb.org.uk/WebPages/PublicFiles/MutationSummary.htm. Accessed April 26, 2013
14. Margaglione M., Castaman G., Morfini M., et al. AICE-Genetics Study Group The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica: 2008; 93 5 722 728 (Pubitemid 351669312)
15. Bolton-Maggs P. H., Pasi K. J. Haemophilias A and B. Lancet: 2003; 361 9371 1801 1809 (Pubitemid 36638432)
16. Rallapalli P. M., Kemball-Cook G., Tuddenham E. G., Gomez K., Perkins S. J. Factor IX Mutation Database. Available at: http://www.factorix.org/. Accessed April 26, 2013
17. Ljung R., Petrini P., Tengborn L., Sjörin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol: 2001; 113 1 81 86 (Pubitemid 32423306)
18. Santagostino E., Mancuso M. E., Tripodi A., et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost: 2010; 8 4 737 743
19. van Dijk K., Fischer K., Van Der Bom J. G., Grobbee D. E., Van Den Berg H. M. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia: 2005; 11 5 438 443 (Pubitemid 41283110)
20. Nilsson I. M., Berntorp E., Löfqvist T., Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med: 1992; 232 1 25 32
21. Biss T. T., Chan A. K., Blanchette V. S., Iwenofu L. N., McLimont M., Carcao M. D. Association of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC) The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia: 2008; 14 5 923 930
22. Quick A. J., Hussey C. V. Hemophilia B (PTC deficiency, or Christmas disease). AMA Arch Intern Med: 1959; 103 5 762 775
23. Tagliaferri A., Di Perna C., Franchini M., Rivolta G. F., Pattacini C. Hemophilia severity score system: validation from an Italian Regional Hemophilia Reference Center. J Thromb Haemost: 2009; 7 4 720 722
24. Nagel K., Walker I., Decker K., Chan A. K., Pai M. K. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia: 2011; 17 6 872 874
25. den Uijl I. EM, Roosendaal G., Fischer K. Insufficient evidence to suggest less stringent therapy in hemophilia B? Blood: 2009; 114 23 4907, author reply 4907-4908
26. White G. C. II, Beebe A., Nielsen B. Recombinant factor IX. Thromb Haemost: 1997; 78 1 261 265 (Pubitemid 27289251)
27. Ewenstein B. M., Joist J. H., Shapiro A. D., et al. Mononine Comparison Study Group Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion: 2002; 42 2 190 197
28. Poon M. C., Lillicrap D., Hensman C., Card R., Scully M. F. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost: 2002; 87 3 431 435 (Pubitemid 34232484)
29. Collins P. W., Fischer K., Morfini M., Blanchette V. S., Björkman S. International Prophylaxis Study Group Pharmacokinetics Expert Working Group Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia: 2011; 17 1 2 10
30. National Hemophilia Foundation MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). National Hemophilia Foundation Web site. Available at: http://www.hemophilia. org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007.Accessed November 4, 2007
31. Manco-Johnson M. J., Abshire T. C., Shapiro A. D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med: 2007; 357 6 535 544 (Pubitemid 47236278)
32. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol: 2007; 138 3 305 315
33. Astermark J. Prevention and prediction of inhibitor risk. Haemophilia: 2012; 18 04 38 42
34. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia: 1998; 4 4 574 576 (Pubitemid 28351888)
35. Ewenstein B. M., Takemoto C., Warrier I., et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood: 1997; 89 3 1115 1116
36. Nathwani A. C., Tuddenham E. G., Rangarajan S., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med: 2011; 365 25 2357 2365
37. Negrier C., Knobe K., Tiede A., Giangrande P., Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood: 2011; 118 10 2695 2701
38. Shapiro A. D., Ragni M. V., Valentino L. A., et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood: 2012; 119 3 666 672
39. Santagostino E., Negrier C., Klamroth R., et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood: 2012; 120 12 2405 2411